C. McNeil

发表

PI3K pathway activation in breast cancer is associated with the basal‐like phenotype and cancer‐specific mortality

Robert L Sutherland, Roger J Daly, Ewan K A Millar, 2010, International journal of cancer.

Pembrolizumab versus Ipilimumab in Advanced Melanoma.

J. Larkin, A. Ribas, C. Blank, 2015, The New England journal of medicine.

The Gift

C. McNeil, Catriona M. McNeil, 2018, Journal of the American Geriatrics Society.

Elevated levels of tumour apolipoprotein D independently predict poor outcome in breast cancer patients

S. O'toole, R. Sutherland, C. Ricciardelli, 2020, Histopathology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Dose modifications in adjuvant chemotherapy for solid organ malignancies: A systematic review of clinical trials

C. McNeil, J. Beith, S. Kao, 2018, Asia-Pacific journal of clinical oncology.

Chemotherapy, surgery and radiotherapy for locally advanced breast cancer

C. McNeil, N. Wilcken, 2003 .

Rate of cancer progression as a predictive marker of efficacy of immunotherapy; an analysis in metastatic non-small-cell lung cancer.

A. Nagrial, C. McNeil, S. Kao, 2019, Immunotherapy.

Catastrophic chemotherapy toxicity leading to diagnosis of Fanconi anaemia due to FANCD1/BRCA2 during adulthood: description of an emerging phenotype

A. Spurdle, R. Scott, P. Guitera, 2021, Journal of Medical Genetics.

Considering the type and timing of breast reconstruction after mastectomy: Qualitative insights into women's decision-making.

C. McNeil, H. Dhillon, I. Juraskova, 2021, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

Cytoplasmic Localization of β-Catenin is a Marker of Poor Outcome in Breast Cancer Patients

S. O'toole, R. Sutherland, E. Musgrove, 2010, Cancer Epidemiology, Biomarkers & Prevention.

Equivocal ALK fluorescence in‐situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing

M. Christie, N. Pavlakis, S. O'toole, 2015, Histopathology.

Dementia in the severely aphasic: Global aphasia without hemiparesis—A stroke subtype simulating dementia

C. McNeil, N. Nagaratnam, 1999 .

National Institutes of Health Consensus Development Conference Statement on Cervical Cancer

W. H. Hall, P. Grigsby, B. Kramer, 1997 .

Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort.

M. Atkins, A. Ribas, F. Hodi, 2016 .

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006.

J. Larkin, A. Ribas, C. Blank, 2016 .

Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL)

P. Ascierto, H. Schmidt, L. Bastholt, 2016 .

Pembrolizumab plus ipilimumab for advanced melanoma : results of the keynote-029 expansion cohort

M. Atkins, A. Ribas, F. Hodi, 2016 .

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

D. Schadendorf, P. Ascierto, M. Smylie, 2020, Journal for immunotherapy of cancer.

Identification of downstream targets of estrogen and c-myc in breast cancer cells.

R. Sutherland, E. Musgrove, C. McNeil, 2008, Advances in experimental medicine and biology.

Estrogens, Cell Proliferation and Breast Cancer

R. Sutherland, E. Musgrove, C. McNeil, 2008 .

Retrospective review of pemetrexed with or without platinum in malignant mesothelioma: The Australian ‘Special Access Scheme’ experience

C. McNeil, R. Hui, M. Burge, 2005 .

Impact of a novel breast cancer survivorship program on patient‐centered outcomes: A single institutional study

C. McNeil, J. Beith, T. Prasanna, 2020, The breast journal.

Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome

H. Rui, C. Haiman, S. O'toole, 2009, Oncogene.

Isolated immune-related pancreatic exocrine insufficiency associated with pembrolizumab therapy.

C. McNeil, D. Parkin, T. Prasanna, 2018, Immunotherapy.

Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management

C. McNeil, N. Shackel, A. Sweeting, 2018, Journal of skin cancer.

Acute management of autoimmune toxicity in cancer patients on immunotherapy: Common toxicities and the approach for the emergency physician

C. McNeil, A. Lomax, 2017, Emergency medicine Australasia : EMA.

Bullous pemphigoid‐like reaction in a patient with metastatic melanoma receiving pembrolizumab and previously treated with ipilimumab

C. McNeil, P. Lowe, S. Anand, 2016, The Australasian journal of dermatology.

4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006.

James R. Anderson, J. Larkin, A. Ribas, 2018 .

Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006

N. Ibrahim, A. Ribas, C. Blank, 2017 .

Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers

S. Fox, J. Reis-Filho, S. O'toole, 2011, Breast Cancer Research.

Nivolumab in previously untreated melanoma without BRAF mutation.

D. Schadendorf, K. Savage, C. Horak, 2015, The New England journal of medicine.

Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma

D. Schadendorf, K. Savage, P. Ascierto, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Case study from the Garvan Institute of Medical Research: long-term survival of a patient with metastatic breast cancer and hypercalcaemia

C. McNeil, J. Grygiel, 2005 .

Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial

I. Judson, B. Seddon, M. Tattersall, 2019, The Lancet. Oncology.

Long-term survival from pembrolizumab (pembro) completion and pembro retreatment: Phase III KEYNOTE-006 in advanced melanoma.

J. Larkin, A. Ribas, C. Blank, 2020 .

Clinical Nurse Consultant Support: Management of patients with melanoma receiving immunotherapy and targeted therapy

C. McNeil, R. Saw, L. Visintin, 2017, Clinical journal of oncology nursing.

PI3K Pathway Activation in Breast Cancer Is Associated with the Basal-Like Phenotype and Cancer-Specific Mortality.

S. O'toole, R. Sutherland, E. Musgrove, 2009 .

Successful management of life‐threatening disseminated intravascular coagulopathy due to metastatic melanoma

C. McNeil, A. Hong, H. Iland, 2014, Internal medicine journal.

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

A. Ribas, C. Blank, A. Arance, 2017, The Lancet.

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.

J. Larkin, A. Ribas, C. Blank, 2019, The Lancet. Oncology.

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.

M. Atkins, A. Ribas, F. Hodi, 2017, The Lancet. Oncology.

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.

D. Schadendorf, P. Ascierto, M. Smylie, 2017, The Lancet. Oncology.

Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer

S. O'toole, R. Sutherland, E. Musgrove, 2011, Oncogene.

Cell cycle machinery: links with genesis and treatment of breast cancer.

R. Sutherland, E. Musgrove, C. McNeil, 2008, Advances in experimental medicine and biology.

BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast

A. Biankin, S. O'toole, R. Sutherland, 2008, British Journal of Cancer.

Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists.

H. Rui, R. Sutherland, S. Henshall, 2008, Cancer research.

The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome

A. Biankin, T. Preiss, R. Sutherland, 2008, Breast Cancer Research.

Review of: c-Myc suppresses p21 WAF1/CIP1 expression during oestrogen signalling and antioestrogen resistance in human breast cancer cells

E. Musgrove, C. McNeil, 2006 .

Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E.

Robert L Sutherland, R. Sutherland, E. Musgrove, 2005, Endocrine-related cancer.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

Hedgehog overexpression is associated with stromal interactions and predicts for poor outcome in breast cancer.

P. Schofield, S. O'toole, R. Sutherland, 2011, Cancer research.

The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy

S. Fox, A. Harris, S. O'toole, 2009, British Journal of Cancer.

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial

D. Schadendorf, K. Savage, P. Ascierto, 2019, JAMA oncology.

The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression

S. Fox, D. Bowtell, N. Waddell, 2011, Breast Cancer Research.

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials

D. Schadendorf, R. Dummer, J. Wolchok, 2017, JAMA oncology.

Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma

S. O'toole, C. McNeil, P. Grimison, 2014, Internal medicine journal.

Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B

M. Atkins, A. Ribas, F. Hodi, 2020, Clinical Cancer Research.

A supportive care intervention for people with metastatic melanoma being treated with immunotherapy: a pilot study assessing feasibility, perceived benefit, and acceptability

C. McNeil, H. Dhillon, S. Kao, 2018, Supportive Care in Cancer.

Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53

S. O'toole, G. Papadatos, R. Sutherland, 2011, British Journal of Cancer.

Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency

S. Lewin, R. Sékaly, C. McNeil, 2018, AIDS.

Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma.

S. Lewin, C. McNeil, S. Palmer, 2015, AIDS.

PDl1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.

J. Madore, J. Wilmott, R. Scolyer, 2016, Pathology.

c-Myc overexpression and endocrine resistance in breast cancer

Margaret Gardiner-Garden, Robert L. Sutherland, James G. Kench, 2006, The Journal of Steroid Biochemistry and Molecular Biology.

Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy

C. McNeil, H. Dhillon, S. Kao, 2018, Supportive Care in Cancer.

Immunotherapy‐induced sarcoidosis in patients with melanoma treated with PD‐1 checkpoint inhibitors: Case series and immunophenotypic analysis

K. Shannon, S. V. van Hal, P. Hersey, 2017, International journal of rheumatic diseases.

Ipilimumab‐induced toxicities and the gastroenterologist

J. Kench, C. McNeil, G. Watson, 2015, Journal of gastroenterology and hepatology.

The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome

S. Vowler, S. Leung, D. Huntsman, 2018, Clinical Cancer Research.

Our Faustian pact with the digital world.

C. McNeil, P. Harnett, 2017, The Lancet. Oncology.

Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers

S. Fox, A. Harris, A. Banham, 2011, Breast Cancer Research.

Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status

Monilola A. Olayioye, S. Fox, M. Christie, 2010, International journal of cancer.

Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.

S. O'toole, G. Papadatos, R. Sutherland, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimise not compromise: The importance of a multidisciplinary breast cancer patient pathway in the era of oncoplastic and reconstructive surgery.

S. O'toole, C. McNeil, J. Beith, 2019, Critical reviews in oncology/hematology.

Outcomes of patients with non‐melanoma solid tumours receiving self‐funded pembrolizumab at Chris O'Brien Lifehouse

C. McNeil, J. Beith, P. Grimison, 2016, Internal medicine journal.

High Notch1 protein expression is an early event in breast cancer development and is associated with the HER‐2 molecular subtype

S. O'toole, R. Sutherland, E. Musgrove, 2010, Histopathology.

Pembrolizumab for the treatment of melanoma

C. McNeil, Sanjeev Kumar, 2015, Expert review of clinical pharmacology.

Programmed death ligand 1 expression in triple‐negative breast cancer is associated with tumour‐infiltrating lymphocytes and improved outcome

J. Madore, J. Wilmott, R. Scolyer, 2016, Histopathology.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, Ludmila V. Danilova, David C. Smith, 2016, Journal of Translational Medicine.

Sentinel node micrometastases in breast cancer: Clinical outcome

C. McNeil, P. Crea, N. Giblett, 2010, Asia-Pacific journal of clinical oncology.

A. Harris, S. O'toole, C. Selinger, 2015, International journal of radiation oncology, biology, physics.

Acute Radiation Skin Toxicity Associated With BRAF Inhibitors.

P. Hersey, R. Kefford, G. Long, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of the anti-endothelin B receptor antibody-drug conjugate DEDN6526A in patients with metastatic or unresectable cutaneous, mucosal, or uveal melanoma

R. Yeh, P. LoRusso, J. Infante, 2019, Investigational New Drugs.

Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development

David R. Croucher, D. Croucher, S. O'toole, 2010, International journal of cancer.

42. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality

S. O'toole, R. Sutherland, E. Musgrove, 2011 .

Patient satisfaction with telehealth consultations in medical oncology clinics: A cross-sectional study at a metropolitan centre during the COVID-19 pandemic

C. McNeil, J. Beith, P. Grimison, 2021, Journal of telemedicine and telecare.

Akinetic mutism and mixed transcortical aphasia following left thalamo–mesencephalic infarction

C. McNeil, N. Nagaratnam, Nages Nagaratnam, 1999, Journal of the Neurological Sciences.

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

D. Schadendorf, K. Savage, C. Horak, 2015, Journal of Translational Medicine.

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

D. Schadendorf, K. Savage, C. Horak, 2015, Journal of Translational Medicine.

Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment.

J. Larkin, A. Ribas, C. Blank, 2017 .

Immunotherapy Bridge 2018 and Melanoma Bridge 2018: meeting abstracts

Hosein, Inge, P. Ascierto, 2019, Journal of Translational Medicine.

Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma

James R. Anderson, J. Larkin, A. Ribas, 2019, Clinical Trials.

What Have We Got to Lose?

C. McNeil, Catriona M McNeil, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Delay in conventional breast cancer treatment associated with alternative therapy usage.

J. Boyages, C. McNeil, F. Collinson, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Misunderstandings, mandatory biopsies, and conflicts of interests in clinical trials: a coercive cocktail?

M. Tattersall, C. McNeil, 2017, The Lancet. Oncology.

Uveitis and Papillitis in the Setting of Dabrafenib and Trametinib Therapy for Metastatic Melanoma: A Case Report

C. McNeil, B. Harrisberg, A. Lomax, 2016, Ocular immunology and inflammation.

Abstract CT101: Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naive advanced melanoma

J. Larkin, A. Ribas, C. Blank, 2015 .

The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome

A. Biankin, T. Preiss, R. Sutherland, 2008, Breast Cancer Research.

CIFeR: A novel Clinician-lead Intervention to address Fear of cancer Recurrence (FCR) in breast cancer survivors.

B. Kiely, P. Butow, C. McNeil, 2020 .

Enhanced RAD21 Cohesin Expression Confers Poor Prognosis and Resistance to Chemotherapy in High Grade Luminal, Basal, and HER 2 Breast Cancers

S. Fox, J. Reis-Filho, S. O'toole, 2014 .

A vision for inclusive and transparent health data in the beyond. Learning

M. Tattersall, I. Judson, B. Seddon, 2019 .

Novel Clinician-Lead Intervention to Address Fear of Cancer Recurrence in Breast Cancer Survivors

B. Kiely, P. Butow, C. McNeil, 2021, JCO oncology practice.